Equillium Inc Analyst & Investor Day Transcript
Good morning, this is Bruce Steel, Chief Executive Officer of Equillium. We appreciate you joining us today for our Analyst and Investor Day presentation featuring Dr. Arash Mostaghimi. We're very pleased to have Dr. Mostaghimi joining us today. We will be discussing some forward-looking topics. We would like to refer you to our filings for further details on our forward-looking statements.
Next slide, please, Steve. So the agenda today, we will be providing a brief pipeline overview, as well as our recent partnership with Ono Pharmaceutical, and then we'll focus on our multi-cytokine platform and development candidates with a specific focus on EQ101, our first-in-class tri-specific peptide inhibitor of IL-2/9/15. This will be presented by Dr. Steve Connelly, our Co-Founder and Chief Scientific Officer. We will follow that with a more detailed discussion on our clinical program of EQ101 targeting alopecia areata that will be presented by Dr. Maple Fung, our Chief Medical Officer.
And then we will engage in a discussion with Dr. Arash Mostaghimi. Again,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |